VR-Based Optokinetic Stimulation in Multiple Sclerosis

NCT07150520 | Not Yet Recruiting

• 1 other identifier: 2025/102
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

The aim of this study is to investigate the acute effects of virtual reality-based optokinetic stimulation on postural sway and motion sickness symptoms in individuals with multiple sclerosis (MS)

Conditions

Multiple Sclerosis

Keywords

multiple sclerosis; vestibular dysfunction; optokinetic stimulation; virtual reality

Outcome Measures

Primary Outcomes (1)

• Postural Sway

  Postural sway will be assessed using the FreeMED force platform under four conditions (bipodal/monopodal, eyes open/closed) before and after a 10-minute virtual reality-based optokinetic stimulation (OKS) session. Parameters include sway path, mediolateral (delta X), and anteroposterior (delta Y) displacement.

  Immediately before and immediately after the 10-minute virtual reality-based optokinetic stimulation session

Study Arms (3)

MS with Central Vestibular Dysfunction

EXPERIMENTAL

Participants with multiple sclerosis who have central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention.

Device: Virtual Reality-Based Optokinetic Stimulation (OKS)

MS without Central Vestibular Dysfunction

EXPERIMENTAL

Participants with multiple sclerosis without central vestibular dysfunction will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention.

Device: Virtual Reality-Based Optokinetic Stimulation (OKS)

Healthy Controls

EXPERIMENTAL

Healthy participants will receive a 10-minute session of virtual reality-based optokinetic stimulation (OKS) using Oculus Quest 2. Postural sway and motion sickness will be measured before and after the intervention

Device: Virtual Reality-Based Optokinetic Stimulation (OKS)

Interventions

Virtual Reality-Based Optokinetic Stimulation (OKS) DEVICE

A 10-minute session of virtual reality-based optokinetic stimulation (OKS) using the Oculus Quest 2 system. The stimulation speed is set at 40°/s and the direction is determined according to Fukuda test results. Postural sway and motion sickness will be assessed before and after the intervention.

Healthy Controls; MS with Central Vestibular Dysfunction; MS without Central Vestibular Dysfunction

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Be an adult aged 18-55 years
• Have a confirmed diagnosis of MS by a neurologist (for MS groups)
• Not have had a relapse in the last 3 months (for MS patients)
• Have an Expanded Disability Status Scale (EDSS) score of ≤ 4 (for MS patients)
• Be a healthy control with no condition preventing participation

You may not qualify if:

• Have peripheral vestibular dysfunction (for MS groups)
• Be older than 55 years
• Have any cardiovascular, orthopedic, neurological, or other condition preventing assessments
• Have a history of neurological disorders, head trauma, or chronic psychiatric conditions (for healthy controls)

Sponsors & Collaborators

• Avrasya University: lead
• Hacettepe University: collaborator

Related Links

• Related Info

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: M.Sc.

Model Details: All participants will receive the same virtual reality-based optokinetic stimulation protocol. Comparisons will be made between MS patients with and without central vestibular dysfunction and healthy controls

Study Record Dates

• First Submitted: August 25, 2025
• First Posted: September 2, 2025
• Study Start: September 15, 2025
• Primary Completion: October 1, 2025
• Study Completion: October 1, 2025
• Last Updated: September 9, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share